Lunit

Lunit is a publicly traded (KOSDAQ: 328130) South Korean medical-AI company focused on cancer — both detection on medical images and biomarkers for oncology therapy selection. Its INSIGHT product line applies deep learning to chest X-rays (nodule and abnormality detection/triage) and mammography (breast-cancer detection), and its SCOPE line analyzes pathology images for immuno-oncology biomarkers. Lunit's tools are FDA-cleared and CE-marked, deployed across dozens of countries, and — distinctively — embedded inside imaging devices from OEM partners, giving it global distribution beyond direct hospital sales.

As one of the few publicly traded pure-play medical-AI companies, Lunit is a useful bellwether for the commercial maturity of cancer-screening AI. Its 2024 acquisition of New Zealand-based Volpara Health added a large US breast-screening footprint and data assets. The company's dual focus — screening AI plus oncology biomarkers — positions it across both radiology and pathology. The usual detection-AI caveats apply (indication-specific clearances, population and image-quality dependence, human-in-the-loop reads), and as a listed company its path also depends on translating clinical adoption into sustainable revenue.